Welcome to our dedicated page for Immunoprecise news (Ticker: IPA), a resource for investors and traders seeking the latest updates and insights on Immunoprecise stock.
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd. (IPA), reports developments in Bio-Native AI, biologics discovery, and AI-driven drug development. Company updates focus on the HYFT® technology stack and the LensAI™ platform, which combine computational analysis with wet-lab validation for epitope mapping, de novo molecular design, in silico vaccine exploration, immunogenicity screening, and population-scale biologics analytics.
Recurring news also covers earnings releases, platform commercialization, partnership and customer activity, and portfolio initiatives such as B Cell Llama™ nanobody discovery and dengue vaccine research. Corporate updates include the transition from the ImmunoPrecise brand to MindWalk, the Nasdaq ticker change to HYFT, and portfolio refinements such as the divestiture of the Netherlands antibody-discovery operations.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announces the resignation of Board member Paul Andreola, effective immediately, for personal reasons unrelated to the company. Andreola has been with the Board since 2018 and will not seek re-election at the upcoming annual general meeting. Jennifer Bath, CEO, expressed gratitude for his contributions, while Andreola remains optimistic about the company's future and intends to support it as a shareholder. The company focuses on novel antibody discovery and developing tailored solutions for diverse disease targets.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has entered into an At-The-Market Distribution Agreement with H.C. Wainwright & Co., allowing for the sale of common shares worth up to US$50 million. This Offering will be conducted under Rule 415 and is aimed at providing funds for the company's growth, working capital, and general corporate purposes. The shares will be sold at market prices, and the TSXV has approved the listing of those shares. The ATM Agreement may not guarantee sales and is subject to market conditions.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) and Pierre Fabre have announced a multi-year research collaboration aimed at developing therapeutic antibodies for up to nine oncology targets. This strategic partnership combines IPA's advanced antibody technologies with Pierre Fabre's expertise in immuno-oncology, enhancing Talem Therapeutics' portfolio. The collaboration includes joint ownership of developed antibodies, with options for licensing, and potential future payments for Talem. Both companies aim to address critical medical needs in cancer treatment.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported a 22% increase in first quarter fiscal 2022 revenues, totaling $4.6 million, compared to $3.8 million in 2020. Research and development costs rose significantly to $1.1 million from $309,213. However, the company faced a net loss of $3.2 million, up from $549,318 last year. As of July 31, 2021, IPA held cash reserves of $40.7 million. CEO Dr. Jennifer Bath highlighted new revenue streams and strategic initiatives amid ongoing investments in R&D and expanding service offerings.
ImmunoPrecise Antibodies Ltd. (IPA) has received a three-year approval for the "Crédit d'Impôt Recherche" (CIR) from the French Ministry of Higher Education and Research for its Oss facility in the Netherlands. This initiative offers R&D tax credits to eligible French companies engaging with IPA Europe. The CIR allows for a 30% credit on R&D expenses up to €100 million and 20% for eligible innovation expenses for SMEs up to €400,000. This accreditation enhances IPA’s appeal in Europe as it provides tax relief to French partners for R&D activities.
ImmunoPrecise Antibodies Ltd. (IPA) announced its participation in the H.C. Wainwright Annual Global Investment Conference from September 13-15, 2021. CEO Jennifer Bath will present the company's business overview and engage in one-on-one meetings with registered investors. The virtual conference serves as a platform for corporate finance and strategic advisory, with H.C. Wainwright being ranked the #1 Placement Agent since 1998. ImmunoPrecise aims to revolutionize antibody discovery through a comprehensive suite of services.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 13-15, 2021. CEO Jennifer Bath will present an overview of the company's activities and engage in one-on-one meetings with institutional investors. The event will be held virtually, and interested investors can register online to attend the presentation on September 10 at 6:00 PM (EDT). ImmunoPrecise aims to revolutionize antibody discovery through innovative technology and comprehensive services.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host an earnings conference call on September 9, 2021, at 4:30 p.m. ET to discuss its Q1 fiscal year 2022 financial results and business highlights. The call follows a press release of the financial results issued prior to the meeting. Investors can submit questions to the company’s investor relations. The call will be accessible via webcast and phone, reinforcing the company's commitment to investor communication and transparency.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced the promotion of Dr. Barry Duplantis to VP of Client Relations and the appointment of Ms. Carla Dahl as VP of Marketing. Dr. Duplantis, with extensive experience in therapeutic antibody campaigns, aims to lead the client relations team and enhance the company's sales lifecycle. Ms. Dahl, bringing over 25 years of experience in marketing, will focus on brand amplification and targeted campaigns to drive revenue. Dr. Jennifer Bath, CEO, expressed confidence in their potential to accelerate the company's growth in North America, Asia, and Europe.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) reported fiscal 2021 results, achieving revenues of $17.9 million, a 27% increase from the previous year. The company's net loss rose to $7.3 million from $5 million in 2020, with increased research and development costs totaling $2 million. Adjusted EBITDA significantly improved to $2.3 million compared to $52,000 in 2020. Cash reserves as of April 30, 2021, were $41.8 million. The company remains focused on expanding its global reach and developing novel therapeutic antibodies.